Withania somnifera (L.) Dunal as Add-On Therapy for COPD Patients: A Randomized, Placebo-Controlled, Double-Blind Study

Background: The current gold-standard therapies for chronic obstructive pulmonary disease (COPD) lack disease-modifying potential and exert adverse side effects. Moreover, COPD patients are at a higher risk of severe outcomes if they get infected by severe acute respiratory syndrome coronavirus 2 (S...

Descripción completa

Detalles Bibliográficos
Autores principales: Singh, Priyam, Salman, Khushtar Anwar, Shameem, Mohammad, Warsi, Mohd Sharib
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Pharmacology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9243480/
https://www.ncbi.nlm.nih.gov/pubmed/35784687
http://dx.doi.org/10.3389/fphar.2022.901710

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9243480/
https://www.ncbi.nlm.nih.gov/pubmed/35784687
http://dx.doi.org/10.3389/fphar.2022.901710

Ejemplares similares